anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present application provides acetone-containing and acetone-free solvent compositions. The compositions may be non-aerosolizable. The compositions may also contain a propellant and be aerosolizable. The aerosolizable compositions may be stored and used in an aerosol container, which can produce a relatively coarse spray containing the aerosolizable composition. In one aspect, the compositions of the present disclosure are cosmetic compositions, e.g., nail polish remover compositions. Also provided are the methods for removing nail polish from a person's nail using the aerosolizable and non-aerosolizable solvent compositions.
INTRODUCTION AND AIM: The advances and the wide use of brain imaging have considerably increased the prevalence of silent brain infarctions (SBI). We aim in this study to determine the prevalence of SBI in patients presenting with acute cardioembolic stroke and the predictive cardiovascular risk factors.
METHODS: This retrospective study included 267 patients presenting with acute cardioembolic stroke in the emergency and/or neurology departments of the Hassan II University Hospital Center. Clinical, biological and echocardiographic characteristics were recorded. All patients were screened for SBI by brain imaging.
RESULTS: The prevalence of SBI in our series was 46%. A group of 203 non-valvular patients and a group of 64 valvular patients were distinguished. In non-valvular group, the average age was 72.97±10.53years. The prevalence of SBI was 45.3%. Forty-four percent of patients with SBI had atrial fibrillation (AF). In multivariate regression analysis, the history of previous stroke, CHA2DS2-VASc Score≥4, enlarged left atrium (LA), the association of AF with enlarged LA and the lability of International Normalized Ratio in patients initially treated with anticoagulants were significantly associated with the occurrence of SBI (P=0.013, P=0.032, P=0.0001, P=0.01, P=0.03, respectively). Territorial location was significantly the most frequent (P=0.007). In valvular group, the average age was 57.19±14.38years. The prevalence of SBI was 48.4%. In multivariate regression analysis, SBI were significantly associated with moderate or severe mitral stenosis (P=0.02) and with the enlarged LA (P=0.02). In all patients, Modified Rankin Scale at 3 months of discharge from the acute stroke was significantly higher (mRS≥3) in patients with SBI (P=0.04).
CONCLUSIONS: SBI requires good management of associated cardiovascular risk factors in a population presenting with initial cardioembolic stroke.
Adjuvants are disclosed for antigens such as viruses, bacteria and parasites, including their metabolic products or parts of the virus, bacteria and parasite structures for the immunization, as well as a process for producing such adjuvants and their uses. The object of the invention is to create adjuvants that in combination with vaccine antigens or with peptidoglycanes in histocompatible composition allow the defence mechanisms in the body to be stimulated to such a large extend that for the first time besides active immunoprophylaxis a even of weak antigens also a general and specific immunotherapy is made possible. The cost of producing the adjuvant should not exceed the usual cost and should ensure the applicability of the vaccine. In relatively weak immuno-incompetent phases of life, a combination of general immunoprophylaxis or the only use of the adjuvant should ensure a high immuno-competence. Residual effects of the adjuvant should not cause any problems. The disclosed adjuvants are oil-in-water emulsions. The oil phase consists of polydimethyl siloxanes and the aqueous phase substantially consists of a biocompatible salt solution. The oil phase is stabilised in the water phase by means of a complex emulsifying agent with HLB value from 9 to 16. The complex emulsifying agent is a combination of aliphatic alcohols of sorbitol with 10 to 100 carbon atoms in the chain and/or of glycerol fatty acid esters and polysorbates. The biocompatible salt solution is a phosphate-buffered sodium chloride solution with EDTA sodium. The combination further contains dimethylsulfoxide. A complete adjuvant is produced by adding peptidoglycanes based on species-specific St. Aureus strains and water-soluble natural and/or synthetic polymers.
INTRODUCTION: Indocyanine green fluorescence imaging (ICG-FI) reduces anastomotic leakage (AL) in rectal cancer surgery. However, no studies investigating risk factors for anastomotic leakage specific to the group using ICG-FI have ever previously been conducted. The purpose of this retrospective multicenter study was to ascertain the risk factors for AL in the group using ICG-FI.
METHODS: A total of 638 patients who underwent laparoscopic or robotic anterior resection for rectal cancer between April 2018 and March 2023 were included in this study. Patients were divided into two groups: the ICG-FI group (n = 269) and the non-ICG-FI group (n = 369) for comparative analysis. The effects of clinicopathological and treatment-related factors on AL in the ICG-FI group were evaluated using both univariate and multivariate analyses.
RESULTS: The incidence of AL in the ICG-FI group was 4.8%. Although there was no significant difference in the incidence of AL between the two groups, it was observed to be lower in the ICG-FI group. A multivariate analysis revealed a preoperative C-reactive protein-to-albumin ratio (CAR) ≥ 0.049 (odds ratio, 3.73; 95% confidence interval, 1.01-13.70; p = 0.048) as an independent risk factor for AL in the ICG-FI group.
CONCLUSIONS: In this study, CAR was the only identified risk factor for AL in the ICG-FI group. It was suggested that CAR could be a criterion for early surgical intervention, prior to the escalation of risks, or for considering interventions such as diverting stoma creation.
EGSPZV2 is a single center, double-blind, placebo-controlled trial. The study is to take place at the Baney Temporary Research Facility (BTRF) located in Baney City. One hundred and thirty-five healthy male and female; adults, adolescents, children and infant volunteers, aged from 6 months to 65 years who live in the Baney district and Malabo city on Bioko Island will be enrolled based on pre-defined inclusion and exclusion criteria implemented according to international ethical standards.

The trial will consist of seven groups (Group 1a: younger adults, ages 18-35; Group 2: older adults, ages 36-65; Group 3: adolescents, ages 11-17; Group 4: older children, ages 6-10; Group 5: younger children, ages 1-5; Groups 6a/b: infants, ages 6 months - 11 months) of volunteers. Vaccination will begin in Group 1a (younger adults), with three doses of 2.7x10\^6 PfSPZ Vaccine given eight weeks apart by DVI. An eighth group (Group 1b: younger adults, ages 18- 35), will be uniquely immunized with the comparator vaccine PfSPZ Challenge given under chloroquine prophylaxis (PfSPZ-CVac approach), rather than with PfSPZ Vaccine. A single PfSPZ-CVac younger adult group (group 1b) is included to provide a direct comparison with PfSPZ Vaccine (group 1a) for the ability to protect against CHMI. Each of the first two groups (1a and 1b) will have 20 participants receiving either PfSPZ Vaccine or PfSPZ Challenge and 6 participants receiving NS placebo by DVI, with treatment allocation randomized and double-blind. Volunteers in Group 1b will receive vaccinations 8 weeks after the initial vaccination of Group 1a. Volunteers in Group 1 (younger adults) will receive CHMI between 10 and 14 weeks post last vaccination (with a window of +/- 7 days on each side) and will be followed for 8 weeks following CHMI.

Group 2 (older adults) will receive three doses of 2.7x10\^6 PfSPZ Vaccine. Group 2 will consist of 12 participants receiving PfSPZ Vaccine and 4 participants receiving NS placebo by DVI, given eight weeks apart. Group 3, 4, 5 and 6b will each have 12 participants receiving three doses of 1.8x10\^6 PfSPZ Vaccine and 4 participants receiving NS, also given eight weeks apart. Group 6a will consist of 3 volunteers who will receive a single dose of 9.0 x10\^5 PfSPZ Vaccine.

Sequential age groups will be staggered to allow assessment of safety and tolerability before further age de-escalation. To assure safety, vaccinations will start in younger adults and will progress to younger and older age groups using staggered start dates at approximately weekly intervals. Age escalation and initial age de-escalation will take place at the same time, hence Group 2 and 3 will be vaccinated at the same time. Progressively younger age groups will then be immunized. The decision to proceed with each of these steps will be made by the study team after a review of safety data from the previously vaccinated group(s). Three Safety Monitoring Committee (SMC) meetings are scheduled to review data prior to initiating the younger children and infant groups.
Ivacaftor is a sensitive CYP3A substrate. Co-administration with ketoconazole, a strong CYP3A inhibitor, significantly increased ivacaftor exposure [measured as area under the curve (AUC)] by 8.5-fold. Based on simulations of these results, a reduction of the KALYDECO dose is recommended for patients 6 months and older taking concomitant strong CYP3A inhibitors, such as ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin, and clarithromycin. KALYDECO is not recommended for patients less than 6 months of age taking strong CYP3A inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)].

Co-administration with fluconazole, a moderate inhibitor of CYP3A, increased ivacaftor exposure by 3-fold. Therefore, a reduction of the KALYDECO dose is recommended for patients 6 months and older taking concomitant moderate CYP3A inhibitors, such as fluconazole and erythromycin. KALYDECO is not recommended for patients less than 6 months of age taking moderate CYP3A inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)].

Co-administration of KALYDECO with grapefruit juice, which contains one or more components that moderately inhibit CYP3A, may increase exposure of ivacaftor. Therefore, avoid food or drink containing grapefruit during treatment with KALYDECO [see Clinical Pharmacology (12.3)].
The invention discloses an intranasal insulin preparation and a preparation method thereof. The intranasal insulin preparation is commonly formed by cell-penetrating peptide dissolved in a liquid-phase carrier and insulin. The cell-penetrating peptide is polypeptide molecule containing specific sequences of amino acids, so that the insulin can be promoted to enter into a human body through a mucosa of a nasal cavity, and the plasma glucose level is regulated. The preparation method of the preparation comprises the main preparing steps of: dissolving the therapeutic dose of insulin by hydrochloric acid; diluting to be required concentration by the liquid-phase carrier; regulating pH to be neutral by sodium hydroxide; mixing with a specific volume of cell-penetrating peptide; filtering and degerming; and storing at low temperature. The preparation can be applied to the surface of the mucosa of the nasal cavity of a person or an animal through an intranasal feeder. Compared with a subcutaneous insulin infusion preparation with the same dosage, according to the intranasal insulin preparation, the relative drug absorption rate is about 80 percent, and the bioavailability reaches more than 60 percent. The cell-penetrating peptide and the insulin have no stimulation on the mucosa of the nasal cavity, the amino acids can be degraded in vivo, the half-life period is short, and the safety is high.
Science demonstrates that the foundation of a person's ability to be innovative, creative, analytical and intellectual is established in the brain during the first few years of life. The brain controls every aspect of human life, from breathing to learning, behaving, adapting and thinking. Because the brain controls all aspects of human life, impaired brain function compromises physical, mental, and emotional health and overall productivity in society. The parent-child or caregiver-child relationship is one of the most important experiences for brain development and cognitive outcomes in young children. This relationship is vital for optimal brain development because of the dependency of neuronal connections on stimulating human interaction. Parental response to their child's verbal or nonverbal cues, frequently called "serve and return", influences whether neural connections are strengthened or eliminated. An example of a positive serve and return scenario is a caregiver or parent's attentive response to a young child's cries through eye contact, acknowledging the child, and meeting the child's need. This type of positive interaction fosters neural connections that are important for communication and social skills.

Many parents do not know or understand the impact their responses have on their child's brain development. While there are many parenting programs that teach parenting skills and behaviors, there were no evidences of any programs that were culturally and economically sensitive to vulnerable families and also educated parents on the brain science as well as equip parents with the skills to be responsive parents Brain Builders Parenting Class will work with both inner city and rural WIC clinics with representative populations of pregnant women and women with children under 1 years old, to provide parenting programs, led by WIC staff focused on brain development.

The study will evaluate the effectiveness of the parenting program in increasing positive parent-child interactions and increasing cognitive achievement in the children. The main goal of this evaluation study is to increase parents' self-efficacy by increasing their knowledge of brain development, improve their skills through observational learning and behavioral capability, provide reinforcement for positive interactions with baby and child, and increase their social support through the group parenting classes and shared experiences. The evaluation study will have two rounds. The first round will take place at recruitment in the WIC Centers. The second round will take place around the time that the child is between 22 and 26 months old. This visit will take place at the WIC clinic.
A series of polyploidizations in higher-order polyploids is the main event affecting gene content in a genome. Each polyploidization event can lead to massive functional divergence because of the subsequent decrease in selection pressure on duplicated genes; however, the causal relationship between multiple rounds of polyploidization and the functional divergence of duplicated genes is poorly understood. We focused on the Triticum-Aegilops complex lineage and compared selection pressure before and after tetraploidization and hexaploidization events. Although both events led to decreased selection pressure on homoeologous gene pairs (compared with diploids and tetraploids), the initial tetraploidization had a greater impact on selection pressure on homoeologous gene pairs than did subsequent hexaploidization. Consistent with this, selection pressure on expression patterns for the initial event relaxed more than those for the subsequent event. Surprisingly, the decreased selection pressure on these homoeologous genes was independent of the existence of in-paralogs within the same subgenome. Wheat homoeologous pairs had different evolutionary consequences compared with orthologs related to other mechanisms (ancient allopolyploidization, ancient autopolyploidization, and small-scale duplication). Furthermore, tetraploidization and hexaploidization also seemed to have different evolutionary consequences. This suggests that homoeologous genes retain unique functions, including functions that are unlikely to be preserved in genes generated by the other duplication mechanisms. We found that their unique functions differed between tetraploidization and hexaploidization (e.g., reproductive and chromosome segregation processes). These findings imply that the substantial number of gene pairs resulting from multiple allopolyploidization events, especially initial tetraploidization, may have been a unique source of functional divergence.
Modified virus-like particles (VLPs) can comprise fusion proteins having sequence from a major coat protein of a papovavirus, e.g. L1 protein of HPV 16 or 18, in which the N-terminal of the sequence derived from the major coat protein is fused to a further peptide sequence. The VLPs can contain a full sequence of an L1 protein, or an L1 sequence with an N-terminal deletion, or an L1 sequence with an aminoacid substitution mutation, and optionally a C-terminal L1 sequence deletion. The peptide sequence fused to the N-terminal can be immunogenic e.g. from a protein of a pathogen such as a virus. The further peptide sequence can provide a binding domain for affinity purification of the VLP. Modified VLPs can retain the native conformation of the VLP structure while also presenting to the immune system of a subject immunised with the modified VLPs an epitope present on an N-terminal extension of the major coat protein sequence. Corresponding polynucleotides, expression vectors, plasmids, vectors and cells containing such polynucleotides are disclosed.
Before therapy with Cefazolin for Injection is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cefazolin, Cephalosporins, penicillins, or other drugs. If this product is given to penicillin‑sensitive patients, caution should be exercised because cross-hypersensitivity among beta-lactam antibiotics has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy. If an allergic reaction to Cefazolin for Injection occurs, discontinue treatment with the drug. Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures, including oxygen, IV fluids, IV antihistamines, corticosteroids, pressor amines and airway management, as clinically indicated. 

Pseudomembranous colitis has been reported with nearly all antibacterial agents, including cefazolin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.

Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is a primary cause of “antibiotic-associated colitis”.

After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an oral antibacterial drug clinically effective against C. difficile colitis.
Participants will be enrolled in a weight loss program based on lifestyle changes. They will be given a 6-month subscription to a calorie-reduced meal replacement program that also offers lifestyle coaching.
The invention discloses a clevidipine butyrate emulsion and a preparation method thereof. The clevidipine butyrate emulsion includes an oil phase and a water phase. The oil phase comprises clevidipine butyrate, long-chain oil and a stabilizer. The water phase comprises an emulsifier and water. A mass ratio of the oil phase and the water phase is 1:11-1:1. The clevidipine butyrate accounts for 0.05-0.5% of the total mass of the clevidipine butyrate emulsion; the long-chain oil accounts for 10-50% of the total mass of the clevidipine butyrate emulsion; the stabilizer accounts for 0.01-0.5% of the total mass of the clevidipine butyrate emulsion; and the emulsifier accounts for 0.5-5.0% of the total mass of the clevidipine butyrate emulsion. The water phase can also include a metal ion chelating agent and/or an isotonic agent. The emulsion can also include a pH adjusting agent. The clevidipine butyrate emulsion is safe and effective, is less in adverse reactions, is high in drug encapsulation efficiency, is good in storage stability, is controllable in preparation processes and is low in contents of impurities. The method is easy to industrially control.
PURPOSE:To automatically realize the entry of an image diagnosis and the input of a disease case by digitizing an image of an X-ray film, executing an image processing, and thereafter, synthesizing it with an electronic card (clinical record). CONSTITUTION:An image of an X-ray film is digitized by a digitizer 7 and registered in a medical image file device 9. In a doctor WS 4, an electronic card (clinical record) is retrieved from an electronic card file 2 and stored in a disk device. Also, image data is retrieved from the medical image file device 9 and displayed on an image WS 10. Subsequently, an instruction is given from the doctor WS 4 to the image WS 10, image processing such as outline extraction, feature extraction, etc., are performed, transferred, displayed in an image opinion display area of the electronic Karte by the doctor WS 4, and the synthesized data is stored in the disk device. In such a way, a medical image and its diagnosis are inputted automatically and can be inputted onto the electronic card.
The present invention relates to novel trefoil factor (tff) peptides, in particular TFF2 peptides. The TFF2 peptides have a moiety covalently attached to Asn15. The moiety can for example be sugar residues or oligosaccharides. TFF2 (spasmolytic protein 1) contains two trefoil domains. Also included is a method for preparing the TFF2 peptides and a pharmaceutical composition comprising the TFF2 peptides. The TFF2 peptides are for increasing the viscosity of mucus layers in mammals and for the use in the treatement of conditions in mammals with damaged or abnormal mucus layres e.g. in the gastrointestinal tract, the respiratory passages, the eye and the urinary system.
Participants received bevacizumab 5 mg/kg intravenously every 2 weeks for 6 months until disease progression or termination of the study. Participants showing a continuous benefit of therapy could receive treatment for a maximum of 12 months.
Subjects received all study treatments: ZTlido and Lidoderm. On Day 1 (Period 1), three ZTlido lidocaine topical systems were applied to the skin on the back for 12 hours. On Day 8 (Period 2), three Lidoderm lidocaine patches were applied to the skin on the back for 12 hours.
The present invention discloses a unique kit for providing a combinational therapeutic product comprising a medical device and a pharmaceutical composition to treat mammal diseases. The medical device is to meet these unmet needs of cleansing out these harmful substances, such as viruses, multiple drug resistant bacteria, fungi, pollen, dusts, or excessive mucus. The pharmaceutical composition adds the required functions of anti-inflammatory, anti-allergy, anti-cancer, promoting membrane healing or immunomodulating, to have the added effect of the medical device. The method of using the combinational product is also disclosed. The new product can be used to prevent and treat a variety of diseases, such as common cold, drug resistant influenza, sinusitis, post nasal drip, virus-triggered asthma, or chronic obstructive pulmonary disease. In addition, the new kit and the process of use are safe and cost effective.